Skip to main content
Krebs Biochemicals & Industries Ltd. logo

Krebs Biochemicals & Industries Ltd. — Investor Relations & Filings

Ticker · KREBSBIO ISIN · INE268B01013 LEI · 335800NILOH3ODIKRO12 BSE.NS Manufacturing
Open in API
Filings indexed 500 across all filing types
Latest filing 2026-05-22 Earnings Release
Country IN India
Listing BSE.NS KREBSBIO

About Krebs Biochemicals & Industries Ltd.

http://www.krebsbiochem.com/

Krebs Biochemicals & Industries Ltd. specializes in the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and biotech products through fermentation and chemical synthesis. As a subsidiary of Ipca Laboratories Limited, the company leverages advanced research and development capabilities to produce high-quality biochemicals. Its core product portfolio includes Ephedrine, Pseudoephedrine, and various statins such as Lovastatin and Simvastatin. The organization focuses on providing cost-effective manufacturing solutions and contract development services for the global pharmaceutical and biotechnology sectors. With a strong emphasis on process optimization and regulatory compliance, the company maintains sophisticated production facilities designed to meet international quality standards.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Earnings Release Classification · 90% confidence The document is an SEBI disclosure under Reg. 30/47 announcing the Board‐approved audited financial results for Q4 and FY ended March 31, 2026, and includes the summary tables of key metrics published in newspapers. This is the initial public release of periodic financial results (net income, EPS, etc.), matching the definition of an Earnings Release. It is not the full annual report or a complete interim report, nor merely a publication notice, but the actual highlights announcement of financial results. FY 2026
2026-05-22 English
The Company has enclosing herewith copy of newspapers advetiement of financial resulst for the quarter and yaer ended 31.03.2026.
Earnings Release Classification · 84% confidence The document is an exchange filing under SEBI LODR providing the company’s Audited Financial Results for the fourth quarter and full year ended March 31, 2026, including income, net profit/loss, earnings per share, and related disclosures. It contains actual periodical results tables—not an Annual Report or full interim report with MD&A—but rather the initial financial results announcement. This aligns with the definition of an Earnings Release (ER). FY 2026
2026-05-22 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is titled “Outcome of Board Meeting – Audited Financial Results for the 4th quarter and financial year ended March 31, 2026,” addressed to stock exchanges under SEBI Listing Regulations. It contains the full standalone P&L for Q4 and FY, audited statements of assets & liabilities, cash flows, and related disclosures. This is not a one‐page highlight release (ER) nor simply an announcement of a report (RPA), but a comprehensive set of audited quarterly/interim financial statements. Therefore, it fits the “Interim / Quarterly Report” category. FY 2026
2026-05-21 English
Audited Results for fiancial yaer ended 31.03.2026
Regulatory Filings Classification · 85% confidence The document is the outcome of a Board Meeting pursuant to SEBI Listing Regulations 30 and 33, disclosing the audited standalone financial results for the quarter and year ended March 31, 2026, and includes full P&L, Balance Sheet, Cash Flow and notes. This is a regulatory announcement of financial results under Indian listing rules rather than a full Annual Report (10-K), an interim/quarterly report for a shorter period, or an investor presentation. It constitutes a general compliance/regulatory filing, so it falls into the Regulatory Filings category (RNS).
2026-05-21 English
Outcome of Board Meeting 21.05.2026
Interim / Quarterly Report Classification · 89% confidence The document is the audited financial results announcement for the quarter and full year ended March 31, 2026, filed under SEBI Listing Regulations. It includes substantive financial statements (income statement, balance sheet, cash flow) and notes, not merely highlights or a link to a full annual report. It is not a full Annual Report (10-K) nor just a summary Earnings Release; it is a detailed periodical financial disclosure for a shorter period (quarterly results plus year-end). Therefore, it fits the Interim/Quarterly Report category. FY 2026
2026-05-21 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Ltd, providing a clarification on the significant price movement of the company's security. It explicitly states that there are no material events or information requiring disclosure under SEBI regulations. The document is short (1851 characters) and serves as a regulatory communication rather than a financial report or announcement of results. It does not contain financial data, management discussion, or any report content. This fits the description of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-04-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.